LOGIN  |  REGISTER
Assertio

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 434.03
-1.29 -0.30
1.58M
257.53M
US$ 111.780B
US$ 596.85
-7.77 -1.29
750,328
108.07M
US$ 64.500B
US$ 289.00
-3.58 -1.22
606,695
128.98M
US$ 37.280B
US$ 581.44
-3.51 -0.60
333,521
59.80M
US$ 34.770B
US$ 99.07
-0.02 -0.02
453,840
239.74M
US$ 23.750B
US$ 25.77
0.36 1.42
2.89M
737.45M
US$ 19.000B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 32.31
-0.52 -1.58
3.27M
444.30M
US$ 14.360B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 308.72
-0.96 -0.31
315,649
44.64M
US$ 13.780B
US$ 21.03
0.51 2.49
1.97M
635.24M
US$ 13.360B
US$ 64.51
-0.27 -0.42
1.53M
192.65M
US$ 12.430B
US$ 42.86
-0.86 -1.97
2.95M
285.58M
US$ 12.240B
US$ 119.12
-1.44 -1.19
855,519
101.25M
US$ 12.060B
US$ 66.16
0.14 0.21
2.60M
178.90M
US$ 11.840B
US$ 58.01
-0.47 -0.80
2.41M
190.58M
US$ 11.060B
US$ 26.72
0.92 3.57
11.15M
384.82M
US$ 10.280B
US$ 160.05
1.95 1.23
343,593
59.81M
US$ 9.570B
US$ 76.09
0.29 0.38
879,177
104.78M
US$ 7.970B
US$ 10.94
0.03 0.27
2.91M
727.95M
US$ 7.960B
US$ 46.50
-0.16 -0.34
2.01M
158.89M
US$ 7.390B
US$ 38.80
0.06 0.15
1.11M
184.80M
US$ 7.170B
US$ 53.75
-0.18 -0.33
1.42M
127.23M
US$ 6.840B
US$ 107.82
-0.45 -0.42
858,240
60.45M
US$ 6.520B
US$ 100.34
-1.17 -1.15
478,410
63.53M
US$ 6.370B
US$ 32.97
0.13 0.40
1.32M
188.99M
US$ 6.230B
US$ 273.35
-3.89 -1.40
283,543
21.81M
US$ 5.960B
US$ 72.69
-1.40 -1.89
1.20M
81.83M
US$ 5.950B
US$ 29.05
0.72 2.54
1.77M
183.45M
US$ 5.330B
US$ 34.24
0.04 0.12
1.33M
155.66M
US$ 5.330B
US$ 33.26
-0.24 -0.72
894,618
157.90M
US$ 5.250B
US$ 104.35
-1.41 -1.33
412,825
48.46M
US$ 5.060B
US$ 26.11
-2.22 -7.84
2.83M
186.89M
US$ 4.880B
US$ 30.05
-0.48 -1.57
670,789
161.80M
US$ 4.860B
US$ 73.23
-0.43 -0.58
329,338
65.62M
US$ 4.810B
US$ 20.16
-1.23 -5.75
1.71M
236.39M
US$ 4.770B
US$ 10.99
0.01 0.09
30,935
411.34M
US$ 4.520B
US$ 33.95
-0.02 -0.06
1.21M
124.64M
US$ 4.230B
US$ 25.53
-0.04 -0.16
1.27M
149.57M
US$ 3.820B
US$ 62.01
-0.40 -0.64
385,368
61.46M
US$ 3.810B
US$ 38.79
-1.26 -3.15
3.34M
95.52M
US$ 3.710B
US$ 30.81
0.19 0.62
640,489
119.31M
US$ 3.680B
US$ 30.49
-0.82 -2.62
1.16M
118.01M
US$ 3.600B
US$ 125.29
-1.39 -1.10
467,823
28.76M
US$ 3.600B
US$ 21.55
3.98 22.65
1.81M
166.39M
US$ 3.590B
US$ 32.50
-0.09 -0.28
601,426
108.94M
US$ 3.540B
US$ 65.21
-4.12 -5.94
1.61M
54.07M
US$ 3.530B
US$ 46.27
0.06 0.13
3.02M
74.39M
US$ 3.440B
US$ 48.97
0.62 1.28
2.32M
69.80M
US$ 3.420B
US$ 35.51
0.10 0.28
501,046
92.34M
US$ 3.280B
US$ 37.53
0.54 1.46
1.32M
85.35M
US$ 3.200B
US$ 73.89
0.59 0.80
581,377
43.12M
US$ 3.190B
US$ 9.94
-0.22 -2.17
99,439
301.94M
US$ 3.000B
US$ 41.60
-1.61 -3.73
1.71M
68.46M
US$ 2.850B
US$ 30.46
-0.26 -0.85
667,268
93.62M
US$ 2.850B
US$ 23.78
-0.54 -2.22
782,992
119.27M
US$ 2.840B
US$ 30.11
0.16 0.53
903,147
92.74M
US$ 2.790B
US$ 45.91
0.09 0.20
778,082
59.60M
US$ 2.740B
US$ 14.56
0.15 1.04
711,970
169.28M
US$ 2.460B
US$ 38.51
-0.03 -0.08
312,345
63.06M
US$ 2.430B
US$ 30.49
0.03 0.10
1.87M
76.24M
US$ 2.320B
US$ 17.78
0.36 2.07
1.68M
124.39M
US$ 2.210B
US$ 10.39
0.32 3.18
5.56M
207.13M
US$ 2.150B
US$ 27.40
-0.21 -0.76
970,602
77.50M
US$ 2.120B
US$ 44.05
-0.26 -0.59
244,530
48.00M
US$ 2.110B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 41.38
0.31 0.75
282,606
49.36M
US$ 2.040B
US$ 64.63
-2.66 -3.95
63,452
30.88M
US$ 2.000B
US$ 13.66
-0.03 -0.22
998,372
143.92M
US$ 1.970B
US$ 2.68
0.03 1.13
8.12M
730.16M
US$ 1.960B
US$ 18.28
-0.23 -1.24
337,323
107.05M
US$ 1.960B
US$ 25.76
-0.46 -1.75
521,356
76.13M
US$ 1.960B
US$ 34.13
-0.37 -1.07
704,433
57.03M
US$ 1.950B
US$ 30.17
0.04 0.13
367,897
64.77M
US$ 1.950B
US$ 15.39
0.08 0.52
1.44M
124.43M
US$ 1.910B
US$ 101.29
-1.16 -1.13
72,876
18.90M
US$ 1.910B
US$ 28.78
-0.21 -0.72
366,121
65.90M
US$ 1.900B
US$ 6.28
-0.06 -0.95
2.91M
298.81M
US$ 1.880B
US$ 40.36
0.18 0.45
240,388
43.42M
US$ 1.750B
US$ 29.59
-0.52 -1.73
590,028
57.03M
US$ 1.690B
US$ 12.62
-0.20 -1.56
466,693
131.84M
US$ 1.660B
US$ 42.97
-0.22 -0.51
344,084
38.23M
US$ 1.640B
US$ 18.68
-0.47 -2.45
1.57M
86.43M
US$ 1.610B
US$ 13.66
-0.10 -0.73
1.60M
117.04M
US$ 1.600B
US$ 31.21
-0.45 -1.42
93,406
50.03M
US$ 1.560B
US$ 15.43
-0.27 -1.72
1.58M
101.12M
US$ 1.560B
US$ 25.21
0.44 1.78
958,573
58.63M
US$ 1.480B
US$ 16.45
-0.02 -0.12
466,881
88.07M
US$ 1.450B
US$ 17.24
0.02 0.12
1.29M
82.81M
US$ 1.430B
US$ 48.04
-0.85 -1.74
206,965
29.76M
US$ 1.430B
US$ 14.52
0.30 2.11
864,399
97.19M
US$ 1.410B
US$ 24.65
0.50 2.07
553,089
57.26M
US$ 1.410B
US$ 15.70
-0.90 -5.42
1.62M
87.03M
US$ 1.370B
US$ 20.37
0.42 2.11
522,097
66.34M
US$ 1.350B
US$ 14.02
-0.57 -3.91
1.15M
94.69M
US$ 1.330B
US$ 15.47
-1.19 -7.14
2.14M
84.64M
US$ 1.310B
US$ 8.84
1.83 26.11
814,132
147.58M
US$ 1.300B
US$ 9.82
-0.08 -0.81
1.39M
131.46M
US$ 1.290B
US$ 7.44
-0.26 -3.38
59,732
170.74M
US$ 1.270B
US$ 10.83
-0.43 -3.82
322,616
115.65M
US$ 1.250B
US$ 19.63
-0.76 -3.73
635,498
63.32M
US$ 1.240B
US$ 11.90
0.14 1.19
1.72M
101.77M
US$ 1.210B
US$ 8.27
-0.07 -0.84
1.64M
143.18M
US$ 1.180B
US$ 18.82
-0.13 -0.69
518,252
62.60M
US$ 1.180B
US$ 7.29
0.18 2.53
6.76M
160.18M
US$ 1.170B
US$ 4.22
0.05 1.20
1.71M
275.78M
US$ 1.160B
US$ 9.65
0.04 0.42
2.51M
117.58M
US$ 1.130B
US$ 7.22
-0.08 -1.10
1.03M
157.22M
US$ 1.130B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 13.67
0.01 0.07
548,276
79.21M
US$ 1.080B
US$ 9.45
0.25 2.72
2.61M
101.85M
US$ 962.480M
US$ 11.21
0.84 8.10
64,682
85.82M
US$ 962.040M
US$ 3.96
-0.03 -0.75
2.64M
236.85M
US$ 937.930M
US$ 4.16
0.26 6.67
715,147
224.34M
US$ 933.250M
US$ 6.09
0.05 0.83
627,136
152.52M
US$ 928.850M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 10.81
0.16 1.50
2.78M
85.36M
US$ 922.740M
US$ 15.07
0.29 1.96
350,971
59.80M
US$ 901.190M
US$ 1.48
0.14 10.45
23.43M
604.50M
US$ 894.660M
US$ 16.39
-0.01 -0.06
67,342
54.23M
US$ 888.830M
US$ 15.66
1.07 7.33
892,306
54.42M
US$ 852.220M
US$ 16.77
-0.16 -0.95
102,639
48.86M
US$ 819.380M
US$ 15.23
-0.27 -1.74
645,412
53.44M
US$ 813.890M
US$ 16.32
-0.34 -2.04
443,348
49.77M
US$ 812.250M
US$ 8.78
0.17 1.97
942,246
91.51M
US$ 803.460M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 11.48
-0.46 -3.85
473,585
68.88M
US$ 790.740M
US$ 28.22
0.06 0.21
74,560
27.50M
US$ 776.050M
US$ 2.25
0.22 10.84
5.32M
335.57M
US$ 755.030M
US$ 17.95
-0.40 -2.18
8,444
41.94M
US$ 752.820M
US$ 12.26
-0.03 -0.24
828,748
60.68M
US$ 743.940M
US$ 4.88
-0.04 -0.81
1.81M
149.08M
US$ 727.510M
US$ 38.31
0.63 1.67
234,878
18.64M
US$ 714.100M
US$ 10.50
0.01 0.10
656
67.84M
US$ 712.320M
US$ 9.99
0.21 2.15
595,163
70.84M
US$ 707.690M
US$ 6.56
-0.03 -0.46
2.17M
106.34M
US$ 697.590M
US$ 20.63
0.16 0.78
335,826
33.70M
US$ 695.230M
US$ 8.84
0.38 4.49
2.68M
76.96M
US$ 680.330M
US$ 7.67
-0.11 -1.41
867,924
84.82M
US$ 650.570M
US$ 4.61
0.10 2.22
1.27M
137.72M
US$ 634.890M
US$ 6.27
-0.02 -0.32
1.02M
100.85M
US$ 632.330M
US$ 4.11
-0.61 -12.92
98,321
153.83M
US$ 632.240M
US$ 5.20
0.08 1.56
435,302
121.55M
US$ 632.060M
US$ 20.74
-0.06 -0.29
356,393
30.43M
US$ 631.120M
US$ 2.83
0.02 0.71
3.89M
218.18M
US$ 617.450M
US$ 3.22
0.01 0.31
771,543
189.49M
US$ 610.160M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 2.00
-1.03 -33.99
2.42M
295.37M
US$ 590.740M
US$ 11.27
-0.52 -4.41
186,706
52.03M
US$ 586.380M
US$ 4.64
-0.06 -1.28
67,178
126.19M
US$ 585.520M
US$ 2.85
-0.04 -1.38
3.59M
204.94M
US$ 584.080M
US$ 14.16
0.12 0.85
398,328
40.51M
US$ 573.620M
US$ 11.42
-0.45 -3.79
546,044
49.42M
US$ 564.380M
US$ 3.23
0.46 16.61
432,716
170.55M
US$ 550.880M
US$ 4.95
-0.03 -0.60
1.80M
110.46M
US$ 546.780M
US$ 18.36
-0.39 -2.08
208,068
29.60M
US$ 543.460M
US$ 6.03
-0.15 -2.43
663,741
89.37M
US$ 538.900M
US$ 7.69
0.17 2.26
1.00M
69.98M
US$ 538.150M
US$ 1.75
-0.01 -0.57
6.06M
304.78M
US$ 533.360M
US$ 8.46
0.54 6.82
794,161
62.42M
US$ 528.070M
US$ 20.25
0.01 0.05
345,633
26.05M
US$ 527.510M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 7.07
0.13 1.87
875,749
73.33M
US$ 518.440M
US$ 7.91
-0.01 -0.13
695,418
65.50M
US$ 518.100M
US$ 6.33
0.03 0.46
1.47M
81.20M
US$ 514.000M
US$ 3.80
0.17 4.68
68,094
133.17M
US$ 506.050M
US$ 9.50
0.02 0.21
433,372
52.97M
US$ 503.220M
US$ 2.93
0.02 0.69
912,549
171.62M
US$ 502.850M
US$ 9.31
0.38 4.26
384,041
53.60M
US$ 499.020M
US$ 10.86
-0.26 -2.34
1.93M
45.47M
US$ 493.800M
US$ 9.86
0.22 2.28
871,140
49.55M
US$ 488.560M
US$ 6.26
0.06 0.97
799,727
77.76M
US$ 486.780M
US$ 9.59
-0.17 -1.74
149,997
50.60M
US$ 485.250M
US$ 2.85
-0.02 -0.52
2.63M
167.38M
US$ 476.200M
US$ 9.49
0.08 0.85
277,832
49.17M
US$ 466.620M
US$ 7.89
0.02 0.25
264,513
58.23M
US$ 459.430M
US$ 5.36
-0.07 -1.29
899,263
85.69M
US$ 459.300M
US$ 8.57
-0.09 -1.04
452,701
53.38M
US$ 457.470M
US$ 19.00
1.09 6.09
1,132
23.94M
US$ 454.860M
US$ 2.00
0.04 2.04
3.04M
223.27M
US$ 446.540M
US$ 6.47
0.22 3.52
2.01M
68.71M
US$ 444.550M
US$ 9.48
0.42 4.64
691,803
44.40M
US$ 420.910M
US$ 5.95
0.08 1.36
685,634
70.57M
US$ 419.890M
US$ 12.51
0.26 2.12
271,953
33.42M
US$ 418.080M
US$ 5.84
-0.34 -5.50
326,987
71.40M
US$ 416.980M
US$ 5.85
0.26 4.65
1.43M
71.12M
US$ 416.050M
US$ 1.53
0.06 4.08
971,179
266.12M
US$ 407.160M
US$ 1.39
0.07 5.30
1.46M
292.87M
US$ 407.090M
US$ 11.12
1.08 10.76
244,814
36.58M
US$ 406.770M
US$ 6.61
-0.19 -2.79
687,145
61.17M
US$ 404.330M
US$ 10.75
0.15 1.42
81,416
37.13M
US$ 399.150M
US$ 5.06
-0.24 -4.53
492,388
78.15M
US$ 395.440M
US$ 15.27
0.16 1.06
204,037
25.64M
US$ 391.520M
US$ 4.62
-0.10 -2.12
430,101
84.69M
US$ 391.270M
US$ 8.10
0.05 0.62
156,999
47.55M
US$ 385.160M
US$ 6.05
-0.11 -1.79
1.01M
63.35M
US$ 383.270M
US$ 5.16
0.15 2.99
380,981
74.24M
US$ 383.080M
US$ 5.60
-0.27 -4.60
542,886
68.25M
US$ 382.200M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 4.24
0.04 0.95
2.35M
89.70M
US$ 380.330M
C$ 5.40
-1.17 -17.81
259,157
70.31M
C$ 379.670M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 0.28
0.01 4.41
891,962
1.32B
US$ 372.240M
US$ 4.38
0.15 3.55
2.31M
84.66M
US$ 370.810M
US$ 8.32
-0.38 -4.37
93,799
44.54M
US$ 370.570M
US$ 2.28
0.04 1.79
545,939
155.15M
US$ 353.740M
US$ 6.55
-0.27 -3.96
883,134
53.81M
US$ 352.460M
US$ 19.73
-1.21 -5.78
271,083
17.61M
US$ 347.450M
US$ 12.80
0.65 5.35
356,338
27.09M
US$ 346.750M
US$ 1.21
-0.01 -0.82
613,009
282.73M
US$ 342.100M
US$ 2.02
0.11 5.76
2.23M
167.80M
US$ 338.960M
US$ 7.48
-0.13 -1.71
1.75M
44.51M
US$ 332.930M
US$ 6.12
-0.13 -2.08
427,839
53.94M
US$ 330.110M
US$ 2.30
0.05 2.00
877,994
141.84M
US$ 325.520M
US$ 7.88
5.57 241.13
35.46M
40.88M
US$ 322.130M
US$ 3.80
0.05 1.33
1.85M
83.94M
US$ 318.970M
US$ 13.59
-0.07 -0.51
40,817
23.22M
US$ 315.560M
US$ 8.61
0.39 4.74
1.90M
36.53M
US$ 314.520M
US$ 2.41
0.07 2.99
4.84M
128.67M
US$ 310.090M
US$ 6.86
-0.54 -7.30
2.03M
45.20M
US$ 310.070M
US$ 2.66
-0.11 -3.97
2.22M
114.86M
US$ 305.530M
US$ 5.94
-0.02 -0.34
155,642
49.95M
US$ 296.700M
US$ 25.11
-0.01 -0.04
17,747
11.78M
US$ 295.800M
US$ 4.23
0.33 8.46
765,911
68.38M
US$ 289.250M
US$ 6.58
0.86 15.03
897,579
43.59M
US$ 286.820M
US$ 1.97
0.03 1.55
112,647
145.46M
US$ 286.560M
US$ 7.62
-0.07 -0.91
115,154
37.42M
US$ 285.140M
US$ 1.87
-0.01 -0.53
626,721
152.10M
US$ 284.430M
US$ 25.70
-0.55 -2.10
160,886
10.95M
US$ 281.420M
US$ 7.10
-0.60 -7.79
9,161
39.63M
US$ 281.370M
US$ 6.29
-0.005 -0.08
35,600
43.64M
US$ 274.500M
US$ 18.04
0.55 3.14
91,007
14.85M
US$ 267.890M
US$ 0.91
0.08 9.76
9.34M
291.32M
US$ 265.390M
US$ 4.84
0.06 1.26
1.84M
54.41M
US$ 263.340M
US$ 1.15
0.001 0.09
2.42M
226.60M
US$ 260.820M
US$ 4.99
0.00 0.00
0
51.59M
US$ 257.430M
US$ 3.96
0.01 0.25
1.98M
64.24M
US$ 254.390M
US$ 4.05
0.04 1.00
319,469
61.44M
US$ 248.830M
US$ 4.24
-0.08 -1.85
359,953
58.31M
US$ 247.230M
US$ 5.42
-0.05 -0.91
752,662
44.48M
US$ 241.080M
US$ 2.85
0.04 1.42
338,608
84.46M
US$ 240.710M
US$ 0.66
0.05 7.56
4.02M
361.49M
US$ 238.580M
US$ 9.15
-0.13 -1.40
58,396
25.73M
US$ 235.300M
US$ 1.25
0.00 0.00
635,124
185.72M
US$ 232.150M
US$ 4.14
0.08 1.97
72,788
55.59M
US$ 230.140M
US$ 1.09
-0.02 -1.80
1.06M
209.67M
US$ 228.540M
US$ 2.27
0.00 0.00
0
100.33M
US$ 227.750M
US$ 2.03
0.63 45.00
5.70M
111.42M
US$ 226.180M
US$ 3.90
-0.11 -2.74
832,652
57.94M
US$ 225.970M
US$ 3.47
-0.16 -4.41
546,332
64.26M
US$ 222.980M
US$ 2.06
0.09 4.57
842,021
106.59M
US$ 219.580M
US$ 20.34
0.45 2.26
67,666
10.79M
US$ 219.470M
US$ 3.87
0.27 7.50
132,178
56.62M
US$ 219.120M
US$ 7.97
-0.32 -3.86
99,183
27.43M
US$ 218.620M
US$ 4.37
0.02 0.46
10,379
49.91M
US$ 218.110M
US$ 35.44
-0.12 -0.34
15,886
6.10M
US$ 216.180M
US$ 7.69
-0.12 -1.47
4,711
27.86M
US$ 214.100M
US$ 30.22
-0.21 -0.69
36,765
6.99M
US$ 211.240M
US$ 3.00
-0.11 -3.57
119,594
70.10M
US$ 210.300M
US$ 2.29
0.02 0.88
793,077
91.18M
US$ 208.800M
US$ 2.11
0.90 74.38
984,308
96.69M
US$ 204.020M
US$ 4.17
-0.005 -0.12
3.20M
48.13M
US$ 200.700M
US$ 1.87
-0.03 -1.32
1.55M
107.42M
US$ 200.340M
US$ 2.46
0.12 5.13
528,846
81.38M
US$ 200.190M
US$ 10.10
3.35 49.63
107,879
19.53M
US$ 197.250M
US$ 9.95
-0.10 -1.00
114,211
19.32M
US$ 192.230M
US$ 2.88
-0.02 -0.69
701,521
66.52M
US$ 191.580M
US$ 4.10
0.04 0.99
582,910
46.03M
US$ 188.720M
US$ 3.22
0.11 3.54
851,168
57.95M
US$ 186.600M
US$ 3.55
0.00 0.00
256,199
52.62M
US$ 186.540M
US$ 4.13
0.03 0.73
109,278
44.79M
US$ 184.980M
C$ 5.16
-0.11 -2.09
15,700
35.62M
C$ 183.800M
US$ 12.54
-0.62 -4.71
51,444
14.48M
US$ 181.580M
US$ 2.45
-2.06 -45.68
1.98M
74.11M
US$ 181.570M
US$ 8.82
-0.51 -5.47
67,191
20.52M
US$ 180.990M
US$ 2.18
0.04 1.87
6,697
82.78M
US$ 180.460M
US$ 3.02
-0.13 -4.13
186,961
59.74M
US$ 180.410M
US$ 1.69
-0.03 -1.74
88,491
105.91M
US$ 178.990M
US$ 3.51
0.17 4.94
271,471
50.04M
US$ 175.390M
US$ 3.66
0.02 0.52
3,605
47.40M
US$ 173.440M
US$ 11.77
0.06 0.51
76,361
14.65M
US$ 172.430M
US$ 4.03
-0.10 -2.42
77,739
42.76M
US$ 172.320M
US$ 4.08
-0.09 -2.16
3.96M
42.20M
US$ 172.180M
US$ 4.24
-0.09 -2.08
41,539
40.44M
US$ 171.470M
US$ 1.41
-0.02 -1.40
549,265
121.01M
US$ 170.620M
US$ 1.70
-0.41 -19.29
163,077
98.94M
US$ 167.700M
US$ 2.13
0.09 4.41
5.09M
78.26M
US$ 166.690M
US$ 3.60
0.05 1.41
339,597
46.23M
US$ 166.430M
US$ 7.50
0.04 0.54
342,977
22.17M
US$ 166.280M
US$ 3.13
0.02 0.58
5,657
52.36M
US$ 163.780M
US$ 2.99
-0.16 -5.08
342,353
54.63M
US$ 163.340M
US$ 1.22
0.06 4.72
1.93M
131.16M
US$ 160.020M
US$ 24.50
8.28 51.05
1.34M
6.53M
US$ 159.990M
US$ 3.25
-0.10 -2.99
234,709
49.09M
US$ 159.540M
US$ 0.80
-0.05 -5.86
3.69M
197.04M
US$ 158.220M
US$ 1.52
0.00 0.00
21,949
100.09M
US$ 152.140M
US$ 3.41
-0.14 -3.94
129,805
44.20M
US$ 150.720M
US$ 7.26
0.24 3.42
200,529
19.99M
US$ 145.130M
US$ 4.04
0.14 3.59
143,270
35.85M
US$ 144.830M
US$ 3.89
-0.05 -1.27
4,133
36.86M
US$ 143.500M
US$ 1.37
-0.05 -3.52
222,607
103.82M
US$ 142.230M
US$ 14.81
0.01 0.07
45,004
9.37M
US$ 138.770M
US$ 1.20
0.03 2.56
966,259
113.89M
US$ 136.670M
US$ 8.69
3.32 61.82
399,374
15.53M
US$ 134.960M
US$ 1.26
-0.34 -21.25
462,637
107.02M
US$ 134.850M
US$ 2.25
0.00 0.00
514,277
59.55M
US$ 133.990M
US$ 1.62
0.12 8.00
1.37M
82.55M
US$ 133.730M
US$ 0.61
0.09 18.37
1.98M
220.42M
US$ 133.350M
US$ 1.45
0.06 4.32
175,653
89.54M
US$ 129.830M
US$ 9.80
0.07 0.72
43,513
13.14M
US$ 128.770M
US$ 1.82
0.29 18.95
7.97M
70.71M
US$ 128.690M
US$ 1.31
0.06 4.80
2.29M
97.93M
US$ 128.290M
US$ 1.84
-0.13 -6.60
128,397
69.36M
US$ 127.620M
US$ 1.77
0.07 3.82
375,023
70.57M
US$ 124.560M
US$ 1.76
0.06 3.53
2.71M
70.38M
US$ 123.870M
US$ 0.42
0.01 2.93
704,818
292.16M
US$ 123.290M
US$ 1.93
0.00 0.00
928,094
63.81M
US$ 123.150M
US$ 5.75
-0.04 -0.69
44,199
21.19M
US$ 121.840M
US$ 0.66
0.03 4.35
1.04M
184.46M
US$ 121.740M
US$ 1.65
-0.06 -3.51
709,550
73.63M
US$ 121.490M
US$ 2.06
0.03 1.48
762,546
56.59M
US$ 116.580M
US$ 0.72
-0.04 -4.85
392,500
161.56M
US$ 116.000M
US$ 2.89
0.19 7.04
1.78M
39.95M
US$ 115.460M
US$ 2.08
0.00 0.00
212,921
54.92M
US$ 114.230M
C$ 1.75
0.04 2.34
5,400
64.94M
C$ 113.640M
US$ 0.87
-0.0007 -0.08
596,934
125.80M
US$ 109.450M
US$ 3.17
-0.08 -2.46
467,582
34.32M
US$ 108.790M
US$ 1.82
0.13 7.69
119,356
58.88M
US$ 107.160M
US$ 0.47
0.01 2.78
715,637
227.48M
US$ 106.920M
US$ 2.47
0.26 11.76
615,222
43.17M
US$ 106.630M
US$ 3.41
0.19 5.90
151,061
30.67M
US$ 104.580M
US$ 2.73
-0.01 -0.36
75,970
37.82M
US$ 103.250M
US$ 0.49
-0.006 -1.20
1.87M
208.65M
US$ 103.070M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 2.97
0.16 5.69
143,900
34.39M
US$ 102.140M
US$ 2.12
0.07 3.41
1.13M
48.11M
US$ 101.990M
US$ 3.08
0.02 0.65
324,849
33.08M
US$ 101.890M
US$ 1.58
0.09 6.04
304,701
62.76M
US$ 99.160M
US$ 1.10
0.08 7.88
552,030
90.55M
US$ 99.150M
US$ 0.78
-0.0006 -0.08
94,347
125.56M
US$ 98.440M
US$ 5.71
0.04 0.71
49,339
16.71M
US$ 95.410M
US$ 0.74
-0.03 -4.43
622,090
127.97M
US$ 94.310M
US$ 1.86
-0.04 -2.11
106,556
49.81M
US$ 92.650M
US$ 7.54
0.13 1.75
83,944
12.18M
US$ 91.840M
US$ 0.76
-0.0045 -0.59
1.30M
119.62M
US$ 90.910M
US$ 0.79
0.02 1.95
880,124
115.21M
US$ 90.790M
US$ 3.79
0.13 3.55
628,668
23.61M
US$ 89.480M
US$ 1.24
0.03 2.48
616,704
71.27M
US$ 88.370M
US$ 2.15
0.04 1.90
37,117
40.31M
US$ 86.670M
US$ 2.84
-0.03 -1.05
29,199
30.48M
US$ 86.560M
US$ 13.56
-0.03 -0.22
10,534
6.36M
US$ 86.240M
US$ 1.76
-0.04 -1.95
988,371
48.88M
US$ 86.030M
US$ 2.49
0.00 0.00
86,000
34.54M
US$ 86.000M
C$ 1.10
-0.05 -4.35
3,798
78.16M
C$ 85.980M
US$ 1.05
0.11 11.32
361,379
81.50M
US$ 85.580M
US$ 1.76
-0.09 -4.62
106,807
48.10M
US$ 84.420M
US$ 2.60
0.04 1.56
17,137
32.20M
US$ 83.720M
US$ 0.92
0.001 0.11
210,789
90.08M
US$ 82.960M
US$ 1.34
0.01 0.75
717,194
60.85M
US$ 81.540M
US$ 1.28
0.00 0.00
105,766
62.76M
US$ 80.330M
US$ 5.81
-0.17 -2.84
23,133
13.70M
US$ 79.600M
US$ 1.20
0.09 8.11
429,371
65.88M
US$ 79.060M
US$ 2.93
0.08 2.81
200,576
26.97M
US$ 79.020M
C$ 0.69
0.04 6.15
466,471
113.60M
C$ 78.380M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
C$ 2.79
0.00 0.00
0
27.40M
C$ 76.450M
C$ 1.02
0.00 0.00
0
74.57M
C$ 76.060M
US$ 4.14
0.00 0.00
0
18.29M
US$ 75.720M
US$ 3.91
0.05 1.30
133,858
19.05M
US$ 74.490M
US$ 0.90
0.06 7.72
793,968
82.46M
US$ 74.460M
US$ 1.39
0.01 0.72
496,742
53.33M
US$ 74.130M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 1.67
0.005 0.30
41,349
44.39M
US$ 73.910M
US$ 4.87
0.05 1.04
143,148
15.00M
US$ 73.050M
US$ 2.02
0.04 2.02
532,867
36.10M
US$ 72.920M
US$ 1.97
0.06 3.14
15,995
36.83M
US$ 72.560M
US$ 1.63
0.10 6.21
15,106
44.27M
US$ 71.940M
US$ 1.20
0.05 4.35
281,305
59.47M
US$ 71.360M
US$ 1.44
0.12 9.09
1.09M
49.09M
US$ 70.690M
US$ 0.27
0.04 15.03
409,874
255.88M
US$ 70.110M
US$ 1.50
0.00 0.00
0
46.60M
US$ 69.900M
US$ 8.42
-0.09 -1.06
114,788
8.25M
US$ 69.460M
US$ 8.47
0.00 0.00
79,787
8.19M
US$ 69.370M
C$ 0.21
-0.01 -4.55
58,100
328.48M
C$ 68.980M
US$ 1.37
-0.02 -1.44
136,892
49.63M
US$ 67.990M
US$ 1.04
0.01 0.97
526,479
65.29M
US$ 67.900M
US$ 1.68
0.00 0.00
5,069
40.30M
US$ 67.700M
US$ 1.38
-0.01 -0.72
8,411
49.05M
US$ 67.690M
US$ 1.87
-0.23 -10.95
292,158
36.18M
US$ 67.660M
US$ 2.43
0.00 0.00
62,449
27.84M
US$ 67.650M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 1.16
-0.06 -4.92
279,778
57.49M
US$ 66.690M
US$ 0.87
0.02 2.59
95,173
75.84M
US$ 65.680M
US$ 2.20
0.07 3.29
137,102
29.75M
US$ 65.450M
US$ 5.73
0.37 6.90
25,621
11.11M
US$ 63.660M
US$ 2.07
-0.14 -6.33
273,091
30.34M
US$ 62.800M
US$ 1.67
0.02 1.21
192,027
37.42M
US$ 62.490M
US$ 1.84
0.19 11.52
151,347
33.84M
US$ 62.270M
US$ 1.03
-0.86 -45.50
362,242
60.08M
US$ 61.880M
US$ 17.00
0.00 0.00
0
3.55M
US$ 60.350M
US$ 0.72
0.02 2.71
429,735
82.40M
US$ 59.250M
US$ 1.57
-0.01 -0.63
572,905
37.41M
US$ 58.730M
US$ 3.44
0.37 12.05
75,339
16.84M
US$ 57.930M
US$ 0.55
-0.02 -3.68
1.21M
103.80M
US$ 56.990M
US$ 1.81
0.00 0.00
0
31.24M
US$ 56.450M
US$ 0.62
-0.02 -2.73
104,377
90.56M
US$ 56.150M
C$ 0.08
0.00 0.00
22,800
701.73M
C$ 56.140M
US$ 1.32
0.00 0.00
124,177
42.51M
US$ 56.110M
US$ 2.49
0.39 18.57
147,581
22.48M
US$ 55.980M
US$ 5.15
-0.21 -3.92
23,421
10.79M
US$ 55.610M
US$ 1.15
0.00 0.00
78,137
48.26M
US$ 55.500M
US$ 5.89
0.48 8.87
7,881
9.39M
US$ 55.310M
US$ 6.18
0.04 0.65
93,635
8.91M
US$ 55.060M
US$ 4.53
0.27 6.34
69,919
11.80M
US$ 53.450M
US$ 1.70
-0.01 -0.58
459,679
31.20M
US$ 53.040M
US$ 0.71
0.01 2.03
22,723
75.00M
US$ 52.880M
US$ 0.33
0.04 15.15
2.06M
158.72M
US$ 52.850M
US$ 1.45
0.00 0.00
760,066
36.24M
US$ 52.550M
US$ 19.45
-0.54 -2.70
3,468
2.61M
US$ 50.760M
US$ 10.10
0.00 0.00
0
5.02M
US$ 50.700M
US$ 1.11
0.03 2.78
355,027
44.56M
US$ 49.460M
US$ 1.06
0.07 7.07
351,595
46.58M
US$ 49.370M
US$ 0.57
-0.0056 -0.97
423,597
85.03M
US$ 48.810M
US$ 4.99
0.02 0.40
224,809
9.72M
US$ 48.500M
C$ 0.68
0.01 1.49
77,227
70.89M
C$ 48.210M
US$ 0.39
0.04 10.39
4.27M
123.53M
US$ 48.180M
US$ 1.98
-0.02 -1.00
135,135
24.29M
US$ 48.090M
US$ 7.52
0.41 5.77
24,934
6.39M
US$ 48.050M
US$ 1.09
0.06 5.83
320,289
44.00M
US$ 47.960M
US$ 1.47
0.03 2.08
211,844
32.60M
US$ 47.920M
US$ 1.73
0.03 1.76
152,433
27.60M
US$ 47.750M
US$ 1.00
-0.07 -6.54
131,571
47.74M
US$ 47.740M
US$ 0.41
0.03 8.49
2.20M
116.36M
US$ 47.710M
US$ 3.80
1.38 57.02
15,790
12.54M
US$ 47.650M
US$ 1.80
-0.02 -0.83
136,367
26.53M
US$ 47.620M
US$ 1.80
0.06 3.45
78,146
26.16M
US$ 47.090M
C$ 0.96
0.01 1.05
500
49.02M
C$ 47.060M
US$ 2.75
-0.01 -0.36
199,227
17.06M
US$ 46.920M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 0.90
-0.0014 -0.16
704,075
51.75M
US$ 46.580M
US$ 2.23
-0.68 -23.37
162,301
20.80M
US$ 46.380M
C$ 0.34
0.00 0.00
0
134.53M
C$ 45.740M
US$ 1.11
-0.01 -0.89
22,187
41.08M
US$ 45.600M
US$ 0.82
0.009 1.10
151,989
55.25M
US$ 45.530M
US$ 1.45
-0.03 -2.03
121,216
31.05M
US$ 45.020M
US$ 0.55
0.08 15.97
412,554
79.97M
US$ 43.900M
C$ 0.38
0.04 11.76
144,801
111.72M
C$ 42.450M
US$ 1.94
0.00 0.00
4,115
21.67M
US$ 42.040M
US$ 0.69
0.02 2.53
890,651
60.34M
US$ 41.510M
US$ 0.90
0.06 7.43
309,739
45.72M
US$ 41.010M
US$ 7.11
0.21 3.04
84,135
5.76M
US$ 40.950M
US$ 1.20
0.02 1.69
121,767
34.08M
US$ 40.900M
US$ 1.64
0.01 0.61
491,227
24.91M
US$ 40.850M
US$ 3.89
0.10 2.64
79,980
10.50M
US$ 40.840M
C$ 0.85
-0.09 -9.57
108,121
47.65M
C$ 40.500M
US$ 2.01
0.03 1.26
86,723
20.16M
US$ 40.420M
US$ 5.37
-0.77 -12.54
904,667
7.14M
US$ 38.340M
US$ 0.91
-0.0091 -1.00
7,718
42.18M
US$ 38.170M
US$ 0.70
0.01 1.78
38,868
54.52M
US$ 38.050M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 4.23
0.22 5.49
16,182
8.74M
US$ 36.970M
US$ 1.00
-0.01 -0.99
3,246
36.18M
US$ 36.180M
US$ 3.35
0.01 0.30
43,351
10.78M
US$ 36.110M
US$ 1.15
-4.21 -78.54
819,809
31.14M
US$ 35.810M
US$ 4.64
-0.01 -0.22
63,442
7.67M
US$ 35.590M
US$ 0.45
0.0059 1.33
1.13M
79.22M
US$ 35.490M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.56
-0.10 -6.02
24,999
22.30M
US$ 34.790M
US$ 1.46
-0.04 -2.67
255,374
23.23M
US$ 33.920M
US$ 1.28
-0.04 -3.03
35,828
26.30M
US$ 33.660M
C$ 0.73
0.01 1.39
2,500
46.03M
C$ 33.600M
US$ 1.26
0.02 1.21
296
26.47M
US$ 33.220M
US$ 0.33
-0.004 -1.20
681,232
100.77M
US$ 33.050M
US$ 0.81
-0.02 -2.30
113,365
40.23M
US$ 32.590M
US$ 2.69
0.06 2.28
331,571
12.09M
US$ 32.520M
US$ 1.53
0.08 5.52
348,259
21.24M
US$ 32.500M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 10.51
-0.49 -4.45
4,021
3.04M
US$ 31.940M
US$ 1.05
0.02 1.94
41,780
29.59M
US$ 31.070M
US$ 0.40
-0.02 -4.99
942,457
77.07M
US$ 30.830M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 0.86
-0.05 -5.86
161,657
35.20M
US$ 30.270M
US$ 2.97
0.05 1.71
7,089
10.14M
US$ 30.120M
US$ 0.86
-0.03 -3.38
541,340
34.96M
US$ 30.000M
US$ 1.23
0.01 0.82
103,818
24.00M
US$ 29.520M
US$ 0.33
0.00 0.00
0
89.34M
US$ 29.390M
US$ 1.89
-0.03 -1.56
10,293
15.49M
US$ 29.280M
US$ 4.00
-0.01 -0.25
11,153
7.30M
US$ 29.200M
US$ 2.08
0.07 3.48
321,015
13.80M
US$ 28.700M
US$ 1.21
0.63 108.19
250,463
23.69M
US$ 28.660M
US$ 2.20
-0.05 -2.22
65,356
12.65M
US$ 27.830M
C$ 0.21
-0.01 -4.55
22,000
127.82M
C$ 26.840M
US$ 15.03
-0.67 -4.27
10,612
1.78M
US$ 26.750M
US$ 0.07
0.005 8.33
970
407.29M
US$ 26.470M
US$ 8.14
0.83 11.35
7,274
3.25M
US$ 26.460M
US$ 0.34
0.01 4.47
465,152
77.45M
US$ 26.260M
US$ 1.84
-0.47 -20.43
29,723
14.23M
US$ 26.150M
US$ 2.25
0.15 7.14
1,850
11.54M
US$ 25.960M
US$ 1.36
-0.02 -1.45
231,717
18.86M
US$ 25.650M
US$ 0.93
0.02 1.64
660,722
27.52M
US$ 25.620M
US$ 0.38
-0.01 -3.36
201,517
66.79M
US$ 25.380M
US$ 0.48
0.07 17.11
804,195
52.74M
US$ 25.260M
US$ 2.90
0.01 0.35
12,736
8.70M
US$ 25.230M
US$ 4.50
-0.009 -0.20
24,867
5.56M
US$ 25.030M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 6.50
0.37 6.04
12,313
3.65M
US$ 23.720M
C$ 0.16
0.00 0.00
0
148.22M
C$ 23.720M
US$ 0.41
0.02 6.49
403,822
58.02M
US$ 23.610M
US$ 0.19
0.0043 2.35
901,895
124.54M
US$ 23.290M
US$ 1.71
-0.04 -2.29
15,293
13.48M
US$ 23.050M
US$ 12.00
-0.30 -2.44
213,113
1.92M
US$ 23.040M
US$ 2.01
-0.03 -1.47
3,580
11.45M
US$ 23.010M
US$ 2.67
0.17 6.80
19,063
8.39M
US$ 22.400M
US$ 1.14
0.04 3.64
25,459
19.08M
US$ 21.750M
US$ 2.59
0.03 0.97
24,711
8.36M
US$ 21.650M
US$ 0.35
0.05 15.95
401,294
61.77M
US$ 21.560M
US$ 1.19
0.02 1.71
56,932
18.06M
US$ 21.490M
US$ 1.48
0.02 1.37
89,016
14.35M
US$ 21.240M
US$ 0.96
-0.02 -1.79
19,526
21.99M
US$ 21.150M
US$ 6.18
0.11 1.81
11,422
3.41M
US$ 21.060M
US$ 0.63
-0.08 -10.76
441,805
33.31M
US$ 21.050M
C$ 0.15
0.00 0.00
0
140.03M
C$ 21.000M
US$ 0.29
0.0013 0.46
449,597
71.01M
US$ 20.380M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 3.69
0.07 1.93
40,335
5.35M
US$ 19.740M
US$ 5.67
0.04 0.71
60,603
3.46M
US$ 19.620M
US$ 3.60
0.08 2.27
45,904
5.43M
US$ 19.550M
US$ 2.45
-0.05 -2.00
175,727
7.98M
US$ 19.550M
US$ 4.09
0.32 8.49
20,012
4.75M
US$ 19.430M
US$ 0.32
0.0041 1.29
785,176
59.12M
US$ 18.980M
US$ 2.79
-0.02 -0.71
16,690
6.80M
US$ 18.970M
C$ 0.04
0.005 16.67
1.02M
541.70M
C$ 18.960M
C$ 0.21
0.00 0.00
7,000
88.52M
C$ 18.590M
US$ 0.62
0.10 18.43
1.06M
30.17M
US$ 18.550M
US$ 1.03
0.03 3.00
214,456
17.77M
US$ 18.300M
US$ 1.37
0.04 3.01
134,834
13.35M
US$ 18.290M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 3.51
0.06 1.80
14,829
5.04M
US$ 17.700M
US$ 0.97
0.01 1.04
60,747
17.55M
US$ 17.020M
US$ 1.99
0.07 3.65
58,654
8.47M
US$ 16.860M
US$ 0.51
0.0087 1.75
14,219
32.69M
US$ 16.510M
US$ 0.25
-0.0002 -0.08
99,339
64.53M
US$ 16.000M
US$ 1.62
0.10 6.58
1.94M
9.66M
US$ 15.650M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
C$ 0.11
-0.02 -15.38
31,700
140.64M
C$ 15.470M
US$ 0.49
0.0001 0.02
100,408
31.06M
US$ 15.190M
US$ 2.20
0.05 2.33
5,792
6.66M
US$ 14.650M
US$ 0.99
-0.01 -1.00
280,592
14.75M
US$ 14.600M
US$ 1.43
0.00 0.00
5,853
10.17M
US$ 14.540M
C$ 0.11
0.02 22.22
65,638
129.86M
C$ 14.280M
US$ 0.37
0.0086 2.38
121,765
38.32M
US$ 14.180M
US$ 0.16
0.02 13.96
100,210
88.13M
US$ 14.100M
US$ 0.40
0.01 2.83
21,474
35.43M
US$ 14.030M
US$ 3.05
-0.17 -5.28
16,157
4.59M
US$ 14.000M
US$ 0.50
-0.0094 -1.86
91,141
28.01M
US$ 13.920M
US$ 0.33
0.0042 1.29
11,923
41.49M
US$ 13.690M
US$ 0.32
-0.0033 -1.04
424,349
41.55M
US$ 13.090M
US$ 1.11
-0.03 -2.28
2,147
11.70M
US$ 13.030M
US$ 0.77
0.03 4.49
161,982
16.85M
US$ 12.970M
C$ 0.13
-0.005 -3.70
85,380
96.40M
C$ 12.530M
US$ 0.33
-0.23 -41.86
711,532
38.27M
US$ 12.440M
US$ 2.02
0.00 0.00
487,318
6.15M
US$ 12.420M
US$ 1.21
-0.03 -2.02
133,545
10.17M
US$ 12.310M
US$ 1.13
0.03 2.73
27,697
10.71M
US$ 12.100M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.23
-0.002 -0.87
129,577
51.37M
US$ 11.710M
US$ 3.53
0.20 6.01
202,867
3.21M
US$ 11.330M
US$ 3.61
0.06 1.69
574
3.12M
US$ 11.280M
C$ 0.04
0.00 0.00
96,000
280.65M
C$ 11.230M
US$ 1.60
0.05 3.23
18,999
6.92M
US$ 11.070M
US$ 2.09
0.00 0.00
0
5.17M
US$ 10.810M
US$ 0.41
0.0088 2.17
574,404
25.92M
US$ 10.730M
C$ 0.03
0.00 0.00
0
418.56M
C$ 10.460M
US$ 0.27
0.0015 0.56
34,072
38.67M
US$ 10.440M
US$ 0.25
0.003 1.20
386,063
41.27M
US$ 10.400M
US$ 1.82
0.17 10.48
370,405
5.70M
US$ 10.390M
US$ 6.23
0.70 12.66
51,137
1.63M
US$ 10.150M
US$ 1.45
0.00 0.00
18,412
6.99M
US$ 10.140M
US$ 0.13
0.007 5.56
721,554
72.48M
US$ 9.640M
US$ 1.02
0.04 4.09
163,685
9.44M
US$ 9.630M
C$ 0.03
0.00 0.00
54,000
308.61M
C$ 9.260M
US$ 8.25
0.16 1.98
34,365
1.12M
US$ 9.240M
US$ 3.07
-0.04 -1.25
3,278
3.00M
US$ 9.210M
US$ 1.46
-0.11 -7.01
200,365
6.29M
US$ 9.180M
US$ 1.66
0.06 3.75
17,966
5.43M
US$ 9.010M
US$ 3.25
0.18 5.86
32,965
2.71M
US$ 8.810M
US$ 1.90
0.02 0.80
68,403
4.58M
US$ 8.680M
C$ 0.06
0.005 9.09
190,000
137.51M
C$ 8.250M
US$ 0.35
0.02 4.57
20,230
23.13M
US$ 8.100M
US$ 7.26
0.50 7.40
38,622
1.10M
US$ 7.990M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 0.84
0.07 9.03
390,272
9.39M
US$ 7.890M
US$ 0.18
0.0081 4.60
145,475
41.75M
US$ 7.680M
US$ 1.84
0.05 2.79
154,015
4.17M
US$ 7.670M
US$ 0.39
-0.03 -7.65
115,902
19.49M
US$ 7.620M
US$ 0.30
-0.02 -6.31
540,202
25.15M
US$ 7.540M
US$ 1.02
-0.02 -2.06
13,752
6.97M
US$ 7.110M
US$ 0.55
-0.03 -5.51
330,430
12.85M
US$ 7.030M
US$ 2.01
0.01 0.50
13,069
3.47M
US$ 6.970M
US$ 0.48
-0.0034 -0.70
172,020
14.09M
US$ 6.780M
US$ 0.75
-0.04 -5.02
239,602
8.99M
US$ 6.720M
US$ 2.49
0.12 5.06
16,209
2.58M
US$ 6.420M
US$ 0.44
0.04 10.22
18.71M
14.50M
US$ 6.380M
US$ 1.04
0.01 0.97
18,309
6.10M
US$ 6.340M
US$ 1.11
-0.07 -5.93
593,984
5.70M
US$ 6.330M
US$ 0.09
0.00 0.00
1.34M
65.46M
US$ 6.150M
US$ 0.72
0.04 6.31
215,961
8.47M
US$ 6.130M
US$ 2.67
0.01 0.38
196,533
2.23M
US$ 5.950M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 0.84
0.005 0.60
127,054
6.90M
US$ 5.800M
US$ 11.45
0.51 4.66
86,783
505,798
US$ 5.790M
US$ 0.96
-0.03 -3.33
12,066
6.03M
US$ 5.770M
US$ 3.50
0.00 0.00
0
1.61M
US$ 5.640M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 0.36
-0.01 -3.73
145,861
15.10M
US$ 5.450M
C$ 0.06
0.005 9.09
261,444
90.29M
C$ 5.420M
US$ 1.95
0.23 13.37
1.00M
2.76M
US$ 5.380M
US$ 7.62
-0.32 -4.03
69,757
696,249
US$ 5.310M
US$ 2.26
-0.09 -3.84
18,525
2.30M
US$ 5.190M
US$ 1.29
0.09 7.50
49,370
3.65M
US$ 4.710M
US$ 3.05
-0.03 -0.86
761
1.54M
US$ 4.690M
US$ 0.72
0.07 10.62
66,544
6.47M
US$ 4.650M
US$ 1.04
-0.04 -3.70
398,792
4.43M
US$ 4.610M
US$ 0.86
-0.04 -4.60
19,841
5.35M
US$ 4.600M
US$ 1.83
-0.05 -2.66
26,261
2.51M
US$ 4.590M
US$ 0.37
-0.01 -2.63
101,014
12.01M
US$ 4.440M
US$ 1.00
0.00 0.00
52,558
4.38M
US$ 4.380M
US$ 1.00
-0.04 -3.85
46,513
4.34M
US$ 4.340M
US$ 4.74
0.25 5.57
9,760
914,234
US$ 4.330M
US$ 0.09
0.00 0.00
0
47.10M
US$ 4.240M
US$ 2.64
0.10 3.94
8,528
1.60M
US$ 4.220M
US$ 3.84
0.06 1.59
37,457
1.09M
US$ 4.190M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 2.96
0.00 0.00
21,841
1.32M
US$ 3.910M
US$ 0.76
-0.01 -1.43
45,264
5.09M
US$ 3.860M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 0.25
-0.10 -28.57
12,500
14.89M
US$ 3.720M
US$ 0.51
0.00 0.00
0
7.24M
US$ 3.710M
US$ 0.01
0.0071 102.90
100
261.79M
US$ 3.670M
US$ 2.99
0.06 2.05
27,149
1.21M
US$ 3.620M
C$ 0.08
-0.005 -5.88
6,000
44.79M
C$ 3.580M
US$ 0.29
-0.01 -3.39
138,610
12.48M
US$ 3.560M
US$ 1.96
-0.02 -1.01
36,054
1.75M
US$ 3.430M
US$ 0.31
0.02 5.19
239,422
10.83M
US$ 3.360M
US$ 1.11
-0.09 -7.50
115,363
3.01M
US$ 3.340M
US$ 1.00
0.03 2.56
6,513
3.22M
US$ 3.220M
US$ 0.96
0.01 1.08
5,802
3.23M
US$ 3.110M
US$ 0.25
0.00 0.00
0
12.27M
US$ 3.070M
US$ 2.21
-0.09 -3.85
2,001
1.36M
US$ 3.010M
US$ 0.18
0.00 0.00
0
16.39M
US$ 3.000M
US$ 0.94
-0.03 -3.09
414,609
3.19M
US$ 3.000M
US$ 1.26
-0.08 -6.15
1,670
2.25M
US$ 2.840M
US$ 3.79
0.03 0.66
1,275
736,431
US$ 2.790M
US$ 2.14
-0.10 -4.46
57,714
1.30M
US$ 2.780M
US$ 0.55
-0.01 -1.80
6,684
4.89M
US$ 2.690M
US$ 1.37
0.02 1.48
3,751
1.93M
US$ 2.640M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.06
-0.02 -27.62
9,234
41.30M
US$ 2.480M
C$ 0.09
0.005 5.88
63,000
27.30M
C$ 2.460M
US$ 0.19
0.002 1.04
59,401
12.59M
US$ 2.440M
US$ 2.83
-0.03 -1.06
465
852,996
US$ 2.410M
US$ 1.45
0.08 5.84
176,301
1.66M
US$ 2.410M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 1.85
-0.05 -2.63
28,470
1.28M
US$ 2.370M
US$ 0.26
-0.01 -5.07
889,102
8.51M
US$ 2.250M
US$ 1.87
0.14 8.09
84,842
1.17M
US$ 2.190M
US$ 0.007
0.00 0.00
0
302.90M
US$ 2.120M
US$ 0.76
-0.005 -0.66
31,429
2.77M
US$ 2.090M
US$ 2.75
0.05 1.85
43,457
724,152
US$ 1.990M
US$ 0.42
0.02 5.32
1.31M
4.75M
US$ 1.980M
US$ 0.14
0.00 0.00
0
14.37M
US$ 1.950M
C$ 0.05
-0.10 -66.67
5,750
38.74M
C$ 1.940M
US$ 0.43
-0.02 -3.93
761,837
4.48M
US$ 1.920M
US$ 0.31
-0.03 -7.72
4.06M
5.90M
US$ 1.850M
C$ 0.02
0.00 0.00
0
121.27M
C$ 1.820M
US$ 1.28
0.09 7.56
255,238
1.30M
US$ 1.660M
US$ 0.99
0.07 7.09
719,368
1.60M
US$ 1.580M
US$ 0.77
-0.0022 -0.29
26,636
2.04M
US$ 1.570M
US$ 0.04
-0.06 -57.00
3,332
36.47M
US$ 1.570M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
C$ 0.01
0.00 0.00
0
141.96M
C$ 1.420M
US$ 0.54
-0.007 -1.27
32,310
2.51M
US$ 1.360M
US$ 0.46
0.004 0.87
208,624
2.78M
US$ 1.290M
US$ 0.002
0.00 0.00
0
635.88M
US$ 1.270M
US$ 0.10
0.00 0.00
0
12.23M
US$ 1.250M
US$ 0.02
-0.12 -84.14
9,003
54.39M
US$ 1.250M
US$ 0.94
0.0098 1.05
348,100
1.27M
US$ 1.200M
US$ 0.24
-0.87 -78.65
19
4.85M
US$ 1.150M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.78
-0.0023 -0.29
30,162
1.44M
US$ 1.120M
US$ 1.20
0.00 0.00
0
863,788
US$ 1.040M
C$ 0.11
0.00 0.00
0
8.86M
C$ 975K
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.03
0.00 0.00
0
29.49M
US$ 826K
US$ 0.24
0.0019 0.79
553,518
3.27M
US$ 795K
US$ 0.03
-0.09 -75.26
2,185
26.83M
US$ 778K
US$ 1.32
0.02 1.54
62.35M
580,840
US$ 767K
US$ 0.17
-0.04 -19.05
331
4.31M
US$ 733K
US$ 0.08
0.001 1.20
7.44M
8.29M
US$ 696K
US$ 0.02
0.00 0.00
0
39.74M
US$ 676K
US$ 0.07
-0.25 -77.36
31,219
6.96M
US$ 501K
US$ 0.22
0.00 0.00
0
2.05M
US$ 451K
US$ 0.30
-0.08 -21.05
4.98M
1.46M
US$ 438K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.007
-0.01 -65.85
1.29M
34.87M
US$ 244K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.003
0.00 0.00
0
61.76M
US$ 185K
US$ 0.001
0.00 0.00
0
172.20M
US$ 172K
US$ 0.04
-0.0004 -0.99
74.93M
3.93M
US$ 157K
US$ 0.03
0.00 0.00
0
3.41M
US$ 109K
US$ 0.001
0.00 0.00
0
100.08M
US$ 100K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.004
-0.01 -100.00
374.32M
4.19M
US$ 17K
US$ 0.09
0.00 0.00
12,560
-
US$ -
US$ 0.12
0.00 0.00
54,809
-
US$ -
US$ 0.00
-0.31 -100.00
3,500
44.57M
US$ -
US$ 0.00
0.00 0.00
0
54.52M
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 0.00
0.00 0.00
0
30.74M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.70M
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
6.58M
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
10.88M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
0.00 0.00
0
112.91M
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.00
-0.001 -100.00
1,500
514.01M
US$ -
US$ 0.26
0.00 0.00
6,433
-
US$ -
US$ 1.25
-0.13 -9.42
4.02M
-
US$ -
C$ 1.85
0.00 0.00
0
-
C$ -
US$ 4.42
-0.21 -4.54
55,119
-
US$ -

Latest Biotechnology Stock News


Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society... Read more


Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi...

REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS)... Read more


Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte... Read more


Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd  Encore presentation planned at EHA 2025 Congress  Kura Oncology to host virtual investor event at 7:30pm ET / 4:30pm PT on June 2nd to discuss the trial results  SAN DIEGO and TOKYO, May 22, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE:... Read more


Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

-  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®,... Read more


PDS Biotechnology Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO)...

Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC Median overall survival for CPS ≥20 is 39.3 months Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC Trial-in-progress currently enrolling patients Conference call on Friday, May 23 at 8:00 a.m. ET to discuss ASCO abstract data sets PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- PDS... Read more


Rigel Pharmaceuticals Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors   Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations... Read more


Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois. An oral presentation... Read more


Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90%  Additional results from dose-finding cohorts will also be presented  ALAMEDA, Calif. / May 22, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination... Read more


Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New data at ASCO from the CARTITUDE-4 study to showcase improved progression-free survival and overall survival with CARVYKTI® versus standard of care (SOC) in key subgroups Preliminary results from ongoing Phase 1 dose-escalation studies of LB2102 in lung... Read more


Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion... Read more


Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) COPENHAGEN, Denmark / May 22, 2025 / Business Wire / Genmab A/S (Nasdaq: GMAB) announced today that it will present new... Read more


Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

CAMBRIDGE, England, & BOSTON / May 22, 2025 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1... Read more


Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) compared... Read more


Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for over forty weeks Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of... Read more


Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company’s positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American... Read more


Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal A

Selected recommended Phase 2 dose: Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal adenocarcinoma Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma Company will host an R&D investor webcast on Monday, June 2 at 11:00 am CDT to review the updated RAMP 205 data as well as updated data on VS-7375 presented at ASCO BOSTON / May 22, 2025 / Business Wire / Verastem Oncology... Read more


Regeneron Pharmaceuticals: Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple... Read more


Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancer ZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological... Read more


Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company’s Phase 1/1b clinical trial of ficerafusp alfa... Read more


Enliven Therapeutics to Present at Upcoming Investor Conferences

BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHAFormat: Fireside ChatDate: Tuesday, May 27, 2025Time: 1:00 p.m. ET Jefferies... Read more


Senti Biosciences to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Live webcast on Thursday, May 29th at 2:40 PM ET SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect:... Read more



Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in

Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002). Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to adverse events. Breakthrough Therapy Designation granted by China’s National Medical Products Administration (“NMPA”) in 2021 supports potential first-in-class approval in CHB-associated liver fibrosis (“CHB... Read more


Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement Healthcare providers and individuals with plaque psoriasis can now choose ZORYVE foam or cream to treat plaque psoriasis anywhere it appears on the body Fifth FDA approval for ZORYVE in less than three years Management will... Read more


Renovaro Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According... Read more


IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region. Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher... Read more


Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET.... Read more


DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

MINNEAPOLIS / May 22, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will present at the upcoming Jefferies Global Healthcare Conference, being held in New York City, NY, June 3 – 5, 2025. Management will be available for one-on-one... Read more


Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage... Read more



Immunome to Present at Upcoming Investor Conferences 

BOTHELL, Wash. / May 22, 2025 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences: TD Cowen 6th Annual Oncology Innovation Summit Presentation Date/Time: May 27, 2025, 6:30 a.m. - 7:00 a.m. PT Goldman Sachs 46th Annual Global Healthcare Conference Presentation Date/Time: June 10, 2025, 11... Read more


Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

SALT LAKE CITY, May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology. The article "LPCN 1148: Rebuilding muscle memory in cirrhosis patients" was contributed by Dr. Kevin... Read more


Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner

Robotic Smell Intelligence Goes Live at Asia's Premier AI Tech Stage SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Ainos, Inc. (NASDAQ:AIMD) (Nasdaq:AIMDW) ("Ainos"), a pioneer in AI-driven scent digitization, announced the official debut of its proprietary AI Nose platform at COMPUTEX 2025, alongside ugo, Inc, Japan's top service robotics company. This milestone marks the first public demonstration of real-time robotic olfaction-a new sensory category poised to... Read more


Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data package Will provide insights into the durability of immune and clinical responses up to three years Extension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of care Minimal costs are associated with the extension as clinical sites are already running... Read more


GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:... Read more


Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY. Jefferies Global Healthcare ConferenceFormat: Presentation and one-on-one investor meet... Read more


Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis...

SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET. To register, click here. The event will feature Rohit Loomba, MD, MHSc (Professor of Medicine, Chief, Division of Gastroenterology and Hepatology,... Read more


Medicus Pharma Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma...

The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin. The study is expected to randomize... Read more


Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects. Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy. Combined data from Studies CL-QRX003-002 and CL-QRX003-003... Read more


PureTech Health to Present at the Jefferies Global Healthcare Conference

BOSTON / May 22, 2025 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, PhD, JD, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30am EDT. A... Read more


Satellos Bioscience Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent steroids Potential trend to improved grip strength observed, with average strength across the study participants doubling from ~2kg to ~4kg Study participants will have the option to enroll into an 11-month, long-term follow-up study Satellos plans to advance SAT-3247 into... Read more


KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

CAMBRIDGE, Mass. & SALISBURY, England / May 22, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29–June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The presentations will include new findings on the potential of sebetralstat... Read more


Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

WATERTOWN, Mass. / May 22, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious... Read more


Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. A webcast of the presentation can be found under the IR Events tab of the Tonix website at ww... Read more


Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... Read more


Unicycive Therapeutics to Present at Upcoming Investor Conferences

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:   Lytham Partners Spring 2025 Investor Conference Type:   Fireside ChatDate/Time:   Thursday, May 29, 2025, at 12:30... Read more


Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

 Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA... Read more


Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

FREMONT, Calif. / May 22, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. “These studies continue to expand the clinical... Read more


Aurinia Pharmaceuticals: New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

LUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 ROCKVILLE, Md. & EDMONTON, Alberta / May 22, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple immunosuppressive therapy with LUPKYNIS® (voclosporin), mycophenolate mofetil (MMF), and low-dose... Read more